IL-1 Inhibition by Anakinra in Acute Gout
Author Information
Author(s): So Alexander, De Smedt Thibaut, Revaz Sylvie, Tschopp Jürg
Primary Institution: Centre Hospitalier Universitaire Vaudois and University of Lausanne
Hypothesis
IL-1 inhibition might be effective in relieving the inflammatory manifestations of acute gout.
Conclusion
Anakinra rapidly relieved the inflammatory symptoms of gout in patients who could not tolerate standard therapies.
Supporting Evidence
- All patients responded rapidly to anakinra within 48 hours.
- No adverse effects were observed during the study.
- Clinical examination showed complete resolution of signs of arthritis in 9 out of 10 patients by day 3.
Takeaway
This study tested a medicine called anakinra to help people with gout feel better quickly, and it worked for everyone in the study.
Methodology
The study involved a pilot, open-label trial where 10 patients with gout received 100 mg of anakinra daily for 3 days.
Potential Biases
Potential bias due to the open-label design and lack of randomization.
Limitations
The study was open-label and lacked a control group, requiring confirmation through randomized controlled trials.
Participant Demographics
Patients had a history of gout and were either intolerant to or had failed standard treatments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website